Operating Segments

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended March 31,
	2018			2017
Revenues
Vaccines/BioDefense	$	809,256		$	1,330,884
BioTherapeutics		310,517			-
Total	$	1,119,773		$	1,330,884
Income/(Loss) from Operations
Vaccines/BioDefense	$	(86,205	)	$	136,600
BioTherapeutics		(1,521,348	)		(1,027,555	)
Corporate		(786,548	)		(847,235	)
Total	$	(2,394,101	)	$	(1,738,190	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	4,480		$	9,769
BioTherapeutics		5,384			9,567
Corporate		1,350			1,714
Total	$	11,214		$	21,050
Interest Income, Net
Corporate	$	16,895		$	4,753
Share-Based Compensation
Vaccines/BioDefense	$	15,668		$	17,998
BioTherapeutics		28,318			49,770
Corporate		63,984			78,859
Total	$	107,970		$	146,627

	As of March 31, 2018		As of December 31, 2017
Identifiable Assets
Vaccines/BioDefense	$	768,868	$	906,416
BioTherapeutics		146,404		116,344
Corporate		6,563,527		8,526,891
Total	$	7,478,799	$	9,549,651

Note 12. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended December 31,
	2017			2016
Revenues
Vaccines/BioDefense	$	4,749,294		$	10,448,794
BioTherapeutics		683,178			-
Total	$	5,432,472		$	10,448,794
Income (Loss) from Operations
Vaccines/BioDefense	$	232,166		$	1,563,884
BioTherapeutics		(4,181,811	)		(3,399,933	)
Corporate		(3,644,154	)		(3,873,533	)
Total	$	(7,593,799	)	$	(5,709,582	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	33,183		$	40,186
BioTherapeutics		30,614			41,395
Corporate		4,766			8,347
Total	$	68,563		$	89,928
Other Income, Net
Corporate	$	29,906		$	1,934,056
Share-Based Compensation
Vaccines/BioDefense	$	76,625		$	99,410
BioTherapeutics		137,319			131,163
Corporate		275,843			344,404
Total	$	489,787		$	574,977

		As of December 31,
		2017		2016
Identifiable Assets
Vaccines/BioDefense	$	906,416	$	1,297,986
BioTherapeutics		116,344		49,422
Corporate		8,526,891		8,919,698
Total	$	9,549,651	$	10,267,105